Treatment Selection in Psoriasis

In ‘Treatment Selection in Psoriasis,’ our panelists focus on the growing body of long-term data supporting sustained disease control and remission in psoriasis, while also highlighting how these data inform real-world treatment selection. The expert faculty discuss emerging evidence demonstrating that a proportion of patients can achieve and maintain complete skin clearance over several years of continuous therapy. This concept of sustained remission is framed as a more stringent and clinically relevant outcome.

The discussion also explores how long-term durability data translate into everyday clinical treatment decisions. With an expanding number of biologic therapies available, clinicians must navigate the choices within limited patient visit times. The faculty highlights the importance of considering individual patient characteristics, such as comorbidities, body weight, presence of psoriatic arthritis, and treatment history, when selecting the most appropriate therapy.

Additionally, the panelists address the evolving expectations around treatment performance, including speed of response, depth of clearance, and durability. The ability to achieve both fast and sustained results is recognized as a key driver of patient satisfaction and quality of life. They also touch on practical considerations, such as dose adjustments and payer dynamics, which can influence treatment selection in real-world settings. The discussion underscores the shift toward personalized, data-driven decision-making in psoriasis care, where long-term outcomes and patient-specific factors guide the pursuit of sustained remission.

Our next episode, ‘Comparing Biologic Classes and Durability in Psoriasis,’ the faculty compares biologic classes in psoriasis, focusing on differences in speed of response and long-term durability. It highlights how emerging head-to-head data and within-class differences are shaping more individualized treatment decisions.